Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin M Posadas

Showing results (71-80 of 112) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2011
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cellsAna R Jensen, Saito Y David, Chuanhong Liao, et al.
Cancer Biology & Therapy|September 3, 2005
A phase II study of perifosine in androgen independent prostate cancerEdwin M Posadas, James Gulley, Philip M Arlen, et al.
Cancer Chemotherapy and Pharmacology|January 15, 2013
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancerEmmanuel S Antonarakis, Elisabeth I Heath, Edwin M Posadas, et al.
Plos One|February 20, 2014
Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancerChen Shao, Chun-Peng Liao, Peizhen Hu, et al.
Asian Journal of Urology|December 22, 2017
Cultured circulating tumor cells and their derived xenografts for personalized oncologyRuoxiang Wang, Gina C Y Chu, Stefan Mrdenovic, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)Fred Saad, Kim N Chi, Neal D Shore, et al.
JAMA Oncology|July 7, 2018
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical TrialKaren A Autio, Robert Dreicer, Justine Anderson, et al.
Advanced Drug Delivery Reviews|March 20, 2018
NanoVelcro rare-cell assays for detection and characterization of circulating tumor cellsYu Jen Jan, Jie-Fu Chen, Yazhen Zhu, et al.
Nature Communications|February 4, 2022
Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasisYiwu Yan, Bo Zhou, Chen Qian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2014
miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancerSajni Josson, Murali Gururajan, Peizhen Hu, et al.
Pageof 12

Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2011
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cellsAna R Jensen, Saito Y David, Chuanhong Liao, et al.
Cancer Biology & Therapy|September 3, 2005
A phase II study of perifosine in androgen independent prostate cancerEdwin M Posadas, James Gulley, Philip M Arlen, et al.
Cancer Chemotherapy and Pharmacology|January 15, 2013
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancerEmmanuel S Antonarakis, Elisabeth I Heath, Edwin M Posadas, et al.
Plos One|February 20, 2014
Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancerChen Shao, Chun-Peng Liao, Peizhen Hu, et al.
Asian Journal of Urology|December 22, 2017
Cultured circulating tumor cells and their derived xenografts for personalized oncologyRuoxiang Wang, Gina C Y Chu, Stefan Mrdenovic, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)Fred Saad, Kim N Chi, Neal D Shore, et al.
JAMA Oncology|July 7, 2018
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical TrialKaren A Autio, Robert Dreicer, Justine Anderson, et al.
Advanced Drug Delivery Reviews|March 20, 2018
NanoVelcro rare-cell assays for detection and characterization of circulating tumor cellsYu Jen Jan, Jie-Fu Chen, Yazhen Zhu, et al.
Nature Communications|February 4, 2022
Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasisYiwu Yan, Bo Zhou, Chen Qian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2014
miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancerSajni Josson, Murali Gururajan, Peizhen Hu, et al.
Pageof 12